Metformin enhances alpelisib sensitivity in HER2+ breast cancer by suppressing cancer stemness and oncogenic signaling
{{output}}
Introduction: Alpelisib, a selective PI3Kα inhibitor that targets PIK3CA mutations, is approved for hormone receptor-positive, HER2-negative breast cancer. However, its therapeutic potential in HER2-positive disease remains unde... ...
